Clinical and functional description of hospitalized patients with Guillain-Barré syndrome in a Chilean university hospital (2020-2024): a descriptive study English

Main Article Content

Jaime Vallejos González
Vicente Abarza de la Paz
Cristóbal Jeldres Cáceres
José Miguel Muñoz Reyes

Keywords

Guillain–Barré Syndrome, Rehabilitation, Disability Evaluation, Activities of Daily Living, Pain

Abstract

Introduction: Guillain-Barré syndrome is the most common cause of acute flaccid paralysis. Although survival is high, a relevant proportion of patients presents functional limitations at hospital discharge, with implications for reha- bilitation. Objective: To describe the clinical and functional profile of patients hospitalized with Guillain-Barré syndrome in a Chilean university hospital. Materials or Patients and Methods: Observational, descriptive, and retros- pective study based on the review of medical records of patients hospitalized between 2020 and 2024. Demographic, clinical, and functional variables were analyzed, including muscle strength (Medical Research Council sum score), disability (Guillain-Barré Disability Score), pain, and support requirements. Prognostic scores EGRIS and EGOS were evaluated. The performance of EGRIS was assessed using a ROC curve. Results: A total of 33 patients were included, with a median age of 58 years (range: 20-89) and a median hospital stay of 26 days (range: 5-516). Axonal variants accounted for 51.5% of cases. Mechanical ventilation was required in 24.2% of patients, and 75% experien- ced pain during hospitalization. MRC scores improved significantly between admission and discharge (p = 0.0007). At discharge, 37.5% of patients were unable to walk independently, and 60.7% had moderate to severe disability (GDS > 3). EGRIS showed good discriminative ability (AUC 0.815; 95% CI: 0.61-0.96). Conclusions: Although neurological improvement occurs during hospitalization, it does not necessarily translate into functional recovery at discharge, highlighting the need for early rehabilitation and continuity of care.

Abstract 0 | PDF (Español (España)) Downloads 0

References

Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Ba- rré syndrome. Lancet. 2021 Mar 27;397(10280):1214- 1228. doi: 10.1016/S0140-6736(21)00517-1. Epub 2021 Feb 26. PMID: 33647239.

van den Berg B, Walgaard C, Drenthen J et al. Guillain- Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014 Aug;10(8):469-82. doi: 10.1038/nrneurol.2014.121. Epub 2014 Jul 15. PMID: 25023340.

Leonhard SE, Mandarakas MR, Gondim FAA et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019 Nov;15(11):671-683. doi: 10.1038/s41582-019-0250-9. Epub 2019 Sep 20. PMID: 31541214; PMCID: PMC6821638.

Ranjani P, Khanna M, Gupta A et al. Prevalence of fatigue in Guillain-Barre syndrome in neurological rehabilitation setting. Ann Indian Acad Neurol. 2014 Jul;17(3):331-5. doi: 10.4103/0972-2327.138521. PMID: 25221406; PMCID: PMC4162023.

Peña L, Moreno CB, Gutiérrez-Alvarez AM. Pain ma- nagement in Guillain-Barre syndrome: a systematic re- view. Neurologia. 2015 Sep;30(7):433-8. doi: 10.1016/j. nrl.2014.04.009. Epub 2014 Jun 12. PMID: 24929444.

Djordjevic G, Stojanov A, Bozovic I et al. Six-month prospective study of quality of life in Guillain-Barre syndrome. Acta Neurol Scand. 2020 Mar;141(3):236- 241. doi: 10.1111/ane.13195. Epub 2019 Nov 8. PMID: 31705530.

Li CMF, Wong S, Fabiano N et al. Systematic Review: Mental Health Outcomes in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuro- pathy. Can J Neurol Sci. 2025 Jun 9:1-10. doi: 10.1017/ cjn.2025.10107. Epub ahead of print.

Khedr EM, Mahmoud DM, Ahmed GK et al. Predictors of long-term health-related quality of life in Guillain- Barré syndrome: A hospital-based study. Clin Neurol Neurosurg. 2023 Dec;235:108026. doi: 10.1016/j. clineuro.2023.108026. Epub 2023 Oct 28. PMID: 37913589.

Sulli S, Scala L, Berardi A et al. The efficacy of re- habilitation in people with Guillain-Barre syndrome: a systematic review of randomized controlled trials. Expert Rev Neurother. 2021 Apr;21(4):455-461. doi: 10.1080/14737175.2021.1890034. Epub 2021 Feb 23. PMID: 33567916.

Kiper P, Chevrot M, Godart J et al. Physical Exer- cise in Guillain-Barré Syndrome: A Scoping Re- view. J Clin Med. 2025 Apr 12;14(8):2655. doi: 10.3390/jcm14082655. PMID: 40283485; PMCID: PMC12028042.

Yousef NM, Adejumo DK, Hazari A, Kandakurti PK. A structured rehabilitation program for functional recovery in Guillain-Barré syndrome: a case report. J Med Case Rep. 2025 Sep 26;19(1):450. doi: 10.1186/s13256-025- 05545-z. PMID: 41013802; PMCID: PMC12465850.

Walgaard C, Lingsma HF, Ruts L et al. Early recog- nition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011 Mar 15;76(11):968-75. doi: 10.1212/ WNL.0b013e3182104407. PMID: 21403108; PMCID: PMC3059137.

Busl KM, Fried H, Muehlschlegel S et al. Guidelines for Neuroprognostication in Adults with Guillain-Barré Syndrome. Neurocrit Care. 2023 Jun;38(3):564-583. https://link.springer.com/article/10.1007/s12028- 023-01707 3. doi: 10.1007/s12028-023-01707-3. Epub 2023 Mar 25. Erratum in: Neurocrit Care. 2023 Jun;38(3):832. doi: 10.1007/s12028-023-01726-0. Erratum in: Neurocrit Care. 2023 Dec;39(3):752. doi: 10.1007/s12028-023-01830-1. PMID: 36964442; PM- CID: PMC10241707.

Doets AY, Walgaard C, Lingsma HF et al. IGOS Consortium. International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Sco- re. Ann Neurol. 2022 Apr;91(4):521-531. doi: 10.1002/ ana.26312. Epub 2022 Feb 21. PMID: 35106830; PM- CID: PMC9306880.

Jacobs BC, van den Berg B, Verboon C et al; IGOS Consortium. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of di- sease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/ jns.12209. PMID: 28406555.

Luijten LWG, Doets AY, Arends S et al; IGOS Consor- tium. Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):300-308. doi: 10.1136/jnnp-2022-329937. Epub 2022 Nov 25. PMID: 36428088.

Cea G, Jara P, Quevedo F. Características epidemio¬lógicas del síndrome de Guillain-Barré en población chilena: estudio hospitalario en un período de 7 años [Clinical features of Guillain-Barré syndrome in 41 patients admitted to a public hospital]. Rev Med Chil. 2015 Feb;143(2):183-9. Spanish. doi: 10.4067/S0034- 98872015000200005. PMID: 25860360.18.

Hughes RAC. Guillain-Barré syndrome: looking back^ and forward. J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):111-112. doi: 10.1136/jnnp-2019-322361. PMID: 31924731.

Walteros DM, Soares J, Styczynski AR et al. Long-term outcomes of Guillain-Barré syndrome possibly asso- ciated with Zika virus infection. PLoS One. 2019 Aug 1;14(8):e0220049. doi: 10.1371/journal.pone.0220049. PMID: 31369576; PMCID: PMC6675241.

Groves KD, Preisig AM, Aldanese A et al. Pain ma- nagement in Guillain-Barré Syndrome: a literatura review. Explor Neurosci. 2025;4:1006114. https://doi. org/10.37349/en.2025.1006114.